Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. chest pain
Show results for
Products
Services
Training
Applications

Companies

News
Articles

Refine by
Date

  • Older

Chest Pain Articles & Analysis

22 news found

Histoplasmosis Infection Risks for Workers & Vulnerable Populations

Histoplasmosis Infection Risks for Workers & Vulnerable Populations

According to the CDC, symptoms may appear between 3 and 17 days after exposure and may include fever, cough, fatigue, chills, headache, chest pain and body aches. The very young, older adults and people with a weakened immune system are at higher risk for developing severe forms of the infection. ...

ByCochrane & Associates, LLC


Histoplasma Infection Risks for Workers and Vulnerable Populations in Puerto Rico

Histoplasma Infection Risks for Workers and Vulnerable Populations in Puerto Rico

According to the CDC, symptoms may appear between 3 and 17 days after exposure and may include fever, cough, fatigue, chills, headache, chest pain and body aches. The very young, older adults and people with weakened immune systems are at higher risk for developing severe forms of the infection. ...

ByCochrane & Associates, LLC


XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

“Patients with refractory angina are forced to live with the ongoing burden of a disease that limits their activities on a daily basis due to chest pain,” said Thomas Povsic, M.D., Ph.D., Duke University cardiologist and National Principal Investigator for the EXACT study. ...

ByXyloCor Therapeutics


XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease

XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease

” Individuals with refractory angina experience pressure or intense pain in the chest due to insufficient blood flow to the heart muscle. ...

ByXyloCor Therapeutics


Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

This comprehensive approach enables physicians to diagnose not only the direct cause of chest pain but also to determine if patients have early-stage heart disease which cannot be seen by alternative methods. ...

ByElucid


XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT

XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT

This restored blood supply could potentially improve patients’ quality of life by enabling them to resume physical activities and it could reduce episodes of chest pain associated with refractory angina. In the Phase 1 portion of the EXACT study, 12 subjects with Canadian Cardiovascular Society (CCS) angina class 2-4 without revascularization options were ...

ByXyloCor Therapeutics


Acutus Medical completes enrollment in IDE trial with its AcQBlate FORCE Sensing Ablation System

Acutus Medical completes enrollment in IDE trial with its AcQBlate FORCE Sensing Ablation System

Right atrial flutter occurs when rapidly firing electrical signals cause the muscles in the heart’s upper chamber (atria) to contract quickly, leading to a rapid heartbeat and can include symptoms such as chest pain, shortness of breath, dizziness, and fainting1. A sustained rapid heartbeat can also put stress on the heart and slow the movement of blood ...

ByAcutus Medical, Inc.


FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

Tell your healthcare provider right away if you have: rash, chest pain, worsening shortness of breath, a feeling of pins and needles or numbness of your arms or legs, or persistent fever. Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. ...

ByRegeneron Pharmaceuticals Inc.


Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Tell your healthcare provider right away if you have: rash, chest pain, worsening shortness of breath, a feeling of pins and needles or numbness of your arms or legs, or persistent fever. Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. ...

ByRegeneron Pharmaceuticals Inc.


Elucid announces American Medical Association (AMA) instates CPT Code for Lipid-Rich Necrotic Core Quantification to Assess Atherosclerotic Plaque Stability

Elucid announces American Medical Association (AMA) instates CPT Code for Lipid-Rich Necrotic Core Quantification to Assess Atherosclerotic Plaque Stability

“Obtaining reimbursement for providers to identify key biomarkers of arterial narrowing and plaque stability will advance the field of cardiovascular medicine and enable clinicians to intercept the disease earlier,” said Blake Richards, Elucid CEO, “Elucid’s mission is to measure flow limitation in the arteries that leads to chest pain and ...

ByElucid


Elucid Eyes Big Opportunity to Save Lives with Software Amidst Major Guideline Changes

Elucid Eyes Big Opportunity to Save Lives with Software Amidst Major Guideline Changes

In a highly anticipated document published online yesterday in Circulation and the Journal of the American College of Cardiology, the Joint Committee on Clinical Practice Guidelines for the American College of Cardiology & American Heart Association released new clinical practice guidelines for managing patients with Acute and Stable chest pain. Backed by ...

ByElucid


BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

These patients experience frequent angina (chest pain) attacks that are uncontrolled by optimal drug therapy but are not suitable candidates for stent placement or bypass surgery, leaving them with no therapeutic options. ...

ByBiocardia, Inc.


Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to no Chest Pain

Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to no Chest Pain

With more than 300 patients treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, vascular dementia, COPD, and pulmonary hypertension, in this one-minute segment Peter recounts how his chest pain dissipated one week after his stem cell treatment, and he recounts how he felt like his life was back to normal after six weeks. ...

ByHemostemix Inc.


XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease

XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease

About Chronic Refractory Angina Chronic angina pectoris occurs when the heart muscle does not receive as much oxygen as it needs for the amount of work it is performing, and this often results in chest pain. This is usually due to coronary artery disease. Patients with chronic angina who are symptomatic despite optimal medical therapy and are no longer eligible ...

ByXyloCor Therapeutics


MagicTouch SCB Granted ‘Breakthrough Device Designation’ for the treatment of Small Coronary Artery Lesions.

MagicTouch SCB Granted ‘Breakthrough Device Designation’ for the treatment of Small Coronary Artery Lesions.

Occlusion of these small vessels (coronary microvascular disease) can diminish blood flow to the heart leading to chest pain or shortness of breath, as well as diffuse chest discomfort similar (and often as debilitating) to those from classic Coronary Artery Disease (CAD). ...

ByConcept Medical Inc.


Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions

Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions

Loculated pleural effusion (LPE) is a condition in which fluid is trapped within the pleural cavity due to fibrinous adhesions, leading to pain, shortness of breath and possibly sepsis. There currently are no approved drug treatment options for this condition. ...

ByLung Therapeutics, Inc.


XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina

XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina

“People with refractory angina are forced to make many sacrifices in their lives as chest pain limits their ability to perform ordinary physical activities,” said Al Gianchetti, President and Chief Executive Officer of XyloCor Therapeutics. “Dosing the first patients in this clinical trial is an important milestone in XyloCor’s efforts to ...

ByXyloCor Therapeutics


Air Quality Detector Can Protect Babies and Elderly from Allergies

Air Quality Detector Can Protect Babies and Elderly from Allergies

Babies, kids and the elderly are especially at risk for breathing diseases for many reasons. They are very susceptible to breathing diseases, all the more we should invest in protecting them from what may cause it. Protect Babies and Elderly from Breathing Diseases The elderly usually suffer from asthma but are often explained as old age. It could also be caused by smoking or bad air quality ...

ByuHoo


Surprising scientific facts about love

Surprising scientific facts about love

On Valentine's Day some of us relish the opportunity to show our loved ones how much we appreciate them while for others the only thing to love about this day is pointing out how commercial and unnecessary it is. No matter which camp you fall into, there is no denying these 10 facts about love as proven by ...

ByPEAK Scientific Instruments Ltd


Fusobacterium Infections Exposed in New Online Video

Fusobacterium Infections Exposed in New Online Video

These conditions may be followed by swollen cervical lymph nodes and a tender and painful neck. Difficulty breathing and chest pain may also be present “Invasive infections due to Fusobacterium may lead to life-threatening diseases,” reported Paul Cochrane, President of Cochrane and Associates, the company behind the IAQ Video ...

ByCochrane & Associates, LLC

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT